Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
| Indexado |
|
||||
| DOI | 10.1093/ANNONC/MDZ063.002 | ||||
| Año | 2018 | ||||
| Tipo | resumen de reunión |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Mok, Tony S. K. | Hombre |
Chinese Univ Hong Kong - China
Prince of Wales Hospital Hong Kong - Hong Kong |
| 2 | Socinski, M. A. | Hombre |
Florida Hosp - Estados Unidos
Florida Hospital Cancer Institute - Estados Unidos |
| 3 | Reck, Martin | Hombre |
German Ctr Lung Res - Alemania
Krankenhaus Großhansdorf - Alemania |
| 4 | Jotte, R. M. | Hombre |
USON Thorac Comm - Estados Unidos
Rocky Mountain Cancer Centers - Estados Unidos |
| 5 | Lim, Darren Wan-Teck | Hombre |
Natl Canc Ctr Singapore - Singapur
National Cancer Center - Singapur |
| 6 | Cappuzzo, Federico | Hombre |
Azienda Unita Sanitaria Locale Romagna - Italia
Ospedale Civile 'Santa Maria delle Croci' - Italia |
| 7 | Orlandi, Francisco J. | Hombre |
Instituto Nacional del Tórax - Chile
Inst Nacl Torax - Chile |
| 8 | Stroyakovskiy, Daniil | Hombre |
Moscow City Oncol Hosp - Rusia
Moscow City Oncology Hospital - Rusia |
| 9 | Nogami, N. | Hombre |
Natl Hosp Org Shikoku Canc Ctr - Japón
National Shikoku Cancer Center Hospital - Japón |
| 10 | Moro-Sibilot, Denis | Hombre |
Ctr Hosp Univ Grenoble Alpes - Francia
Centre Hospitalier Universitaire de Grenoble - Francia |
| 10 | Rodriguez-Abreu, Delvys | - |
Univ Las Palmas Gran Canaria - España
Complejo Hospitalario Universitario Insular Materno-Infantil - España |
| 11 | Moro-Sibilot, Denis | Hombre |
Ctr Hosp Univ Grenoble Alpes - Francia
Centre Hospitalier Universitaire de Grenoble - Francia |
| 12 | Thomas, Christian A. | Hombre |
New England Canc Specialists - Estados Unidos
New England Cancer Specialists - Estados Unidos |
| 13 | Barlesi, F. | Hombre |
Aix Marseille Univ - Francia
Faculte de Medecine de Marseille Universite de la Mediterranee - Francia |
| 14 | Finley, Gene | Hombre |
Allegheny Hlth Network Canc Inst - Estados Unidos
Allegheny Health Network Cancer Institute - Estados Unidos |
| 15 | Lee, A. T. | Hombre |
Genentech Inc - Estados Unidos
Genentech Incorporated - Estados Unidos |
| 16 | Shankar, G. | Mujer |
Genentech Inc - Estados Unidos
Genentech Incorporated - Estados Unidos |
| 17 | Yu, W. | - |
Genentech Inc - Estados Unidos
Genentech Incorporated - Estados Unidos |
| 18 | Kowanetz, Marcin | Hombre |
Genentech Inc - Estados Unidos
|
| 19 | Lin, W. | - |
Genentech Inc - Estados Unidos
|
| 20 | Nishio, Makoto | Hombre |
Japanese Fdn Canc Res - Japón
Cancer Institute Hospital of Japan Foundation for Cancer Research - Japón |
| Fuente |
|---|
| F. Hoffmann-La Roche, Ltd. |
| Pfizer |
| ONO Pharmaceutical |
| Meso Scale Diagnostics |
| Novartis Pharma |
| F. Hoffmann-La Roche |
| Roche |
| Takeda Pharmaceutical Company |
| Kyowa Hakko Kirin |
| Agradecimiento |
|---|
| F. Hoffmann-La Roche. |
| Disclosure: M. Reck: Speakers bureau, consulting, advisory role: Roche, Lilly, Pfizer, BI, AZ, MSD, BMS, Merck, Novartis, Celgene; Other (support of parent study, funding of editorial support): Roche. R. Jotte: Speakers bureau; travel, accommodations, expenses: Bristol-Myers Squibb; Other (support of parent study, funding of editorial support): Roche. T.S.K. Mok: Honoraria, consult/ad role, research: AZ, BI, BMS, Merck, NVS, Pfizer, Roche/GNE; Honoraria, consult/ad role: LLY; Consult/Ad Role: ACEA, Celgene, geneD, Ignyta, OGXI, Vertex; Consult/ad role, research: Clovis, SFJ; Research: Eisai, Taiho; Stock: Sanomics, Hutch. D.W-T. Lim: Honoraria: AZ, BI, Novartis, MSD, Pfizer, Roche, Takeda, Taiho; Research grants (institution): BMS; Stock: Clearbridge Biomedics Pte Ltd, Mesh Bio Pte Ltd; Other (support of parent study, funding of editorial support): Roche. F. Cappuzzo: Speakers/Advisory board: Roche, AZ, BMS, Pfizer, MSD, Takeda; Other (support of parent study, funding of editorial support): Roche. F. Orlandi: Consult/ad role: AZ, Lilly; Consult/ad role, travel, research: Roche, BMS, MSD; Consult/ad role, travel: Pfizer; Speaker, travel, research: MedImm; Research: Amgen, BI, Astellas, Celltrion. D. Stroyakovskiy, C.A. Thomas: Support of parent study, funding of editorial support: Roche. N. Nogami: Honoraria: AZ, Pfizer, Ono Pharmaceutical, Kyowa Hakko Kririn, Taiho, Chugai, Eli Lilly, BI, MSD; Other (support of parent study and funding of editorial support): Roche. D. Rodríguez-Abreu: Speakers bureau: MSD, Roche, BMS, AZ, Pfizer; Other (support of parent study and funding of editorial support): Roche. D. Moro-Sibilot: Honoraria; Consulting/advisory role, travel, accommodations, expenses: Roche, MSD, Pfizer, BMS, AZ; Honoraria, consulting/advisory role: Novartis, Lilly; Other (support of parent study, funding of editorial support): Roche. F. Barlesi: Support of parent study, funding of editorial support: Roche; Personal fees: AZ, BMS, BI, Clovis, Lilly, Roche, Novartis, Merck, MSD, Pierre Fabre, Pfizer, Takeda; Consulting/advisory: MSD, Takeda. G. Finley: Speakers: BMS, BI, Astellas Medivation, Merck; Support of parent study, funding of editorial support: Roche. M. Nishio: Speakers/Ad board, research grant: Ono Pharma, BMS, Pfizer, Chugai, Lilly, Taiho, AZ, MSD, Novartis; Speakers/Ad board: BI, Sankyo, Merck; Research Grant: Astellas; Support of parent study, funding of editorial support: Roche. A. Lee: Employee/Stock: Genentech; Support of parent study, funding of editorial support: Roche. G. Shankar, W. Yu: Employee: Genentech; Support of parent study, funding of editorial support: Roche. M.A. Socinski: Honoraria/speakers bureau/research funding: Genentech; Support of parent study, funding of editorial support: Roche. |
